JNJ EPS
Net income divided by diluted shares outstanding — the per-share profit earned each quarter.
EPS
Latest: $2.27 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.33 |
| 2020Q4 | $0.65 |
| 2021Q1 | $2.32 |
| 2021Q2 | $2.35 |
| 2021Q3 | $1.37 |
| 2021Q4 | $1.77 |
| 2022Q1 | $1.93 |
| 2022Q2 | $1.80 |
| 2022Q3 | $1.68 |
| 2022Q4 | $1.32 |
| 2023Q1 | -$0.03 |
| 2023Q2 | $1.96 |
| 2023Q3 | $10.21 |
| 2023Q4 | $1.58 |
| 2024Q1 | $1.34 |
| 2024Q2 | $1.93 |
| 2024Q3 | $1.11 |
| 2024Q4 | $1.41 |
| 2025Q1 | $4.54 |
| 2025Q2 | $2.29 |
| 2025Q3 | $2.12 |
| 2025Q4 | $2.10 |
| 2026Q1 | $2.14 |
| 2026Q2 | $2.27 |
Other JNJ Charts
More quarter-by-quarter fundamentals for Johnson & Johnson
1 / 10
Revenue
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Latest EPS: $2.27 (2026Q2); -0.9% YoY; +4.0% CAGR since 2011Q1 (15.25y).
Across the 62 quarters from 2011Q1 to 2026Q2, EPS ranged from -$3.91 in 2017Q4 to $10.21 in 2023Q3.
Chart and table show the latest 24 of 62 quarters.